Clinical journal of gastroenterology
Cure8 research brief
Why This Matters
Identifying a genetic cause (XIAP frameshift variant) helped explain why anti‑TNF drugs failed and why blocking IL‑12/23 with ustekinumab led to improvement; that connection could influence treatment choices for similar monogenic IBD cases.
Who Should Pay Attention
Pediatric patients with early‑onset or atypical IBD, caregivers, gastroenterologists managing biologic‑refractory IBD, clinical geneticists, and researchers studying monogenic IBD and immune pathways.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
A pediatric patient with a novel pathogenic frameshift XIAP variant had IBD that was refractory to anti‑TNF therapy, implying a non‑TNF‑dominant inflammation. The treating team used ustekinumab (an IL‑12/23 inhibitor) after standard therapies failed and observed sustained clinical and endoscopic improvement in this case.
The authors emphasize that hematopoietic stem cell transplantation is the only curative option for XIAP deficiency, but targeted biologic therapy guided by genetic findings may inform individualized treatment while weighing risks and benefits.
This case is presented as a single‑patient report that illustrates how genetic diagnosis plus treatment response can reveal disease pathways rather than as definitive proof of ustekinumab efficacy for all XIAP‑associated IBD.
Keep In Mind
This is a single case report (abstract level) published in a peer‑reviewed journal; it suggests a hypothesis about disease mechanism and treatment direction but does not constitute proof of general efficacy. Hematopoietic stem cell transplantation remains the only curative therapy for XIAP deficiency.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical journal of gastroenterology
AuthorsNatsuki Ito, Takahiro Kudo, Hidetaka Eguchi +4 more
InstitutionDepartment of Pediatrics, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113- 8421, Japan.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 22, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Human and animal rights: All procedures were conducted in accordance with the principles of the Declaration of Helsinki. Informed consent: Written informed consent was obtained from the patient for the publication of this article.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The ImproveCareNow Registry: Prediction of remission rates in paediatric Crohn's disease.
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
Assessing the effectiveness of biologics in biologic-naïve patients with isolated small bowel Crohn's disease by double-balloon endoscopy.
The findings give clinicians and patients data on how often biologic therapy leads to endoscopic remission in biologic‑naïve patients with isolated small‑bowel Crohn's disease, and they suggest similar effectiveness...
Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries.
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.